S7of pembrolizumab in kr is 1M, 1.3M, 999K, 795K, and 816K, respectively. Among all the indicated population, the weighted cost per QALY was kr 1M/QALY. The results of sensitivity analyses for other key model parameters were robust. ConCluSionS: A holistic cost-effectiveness model of multi-indication drugs provides HTA bodies a useful tool to evaluate the overarching value of anti-cancer drugs and to alleviate the burden of repetitive appraisals in the era of targeted therapies. Analyses show the cost-effectiveness of pembrolizumab vary across indications due to the differential clinical profiles and demonstrate overall cost-effectiveness across indicated indications in Norway. HT3Using Real-WoRld evidence foR HealTH TecHnology assessmenT sUbmissions: lessons and insigHTs fRom RevieW of nice's TecHnology assessmenT RepoRTs (2016)(2017)